
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
In the 30 years since the first issue of Contemporary Pediatrics, the mortality rate for all pediatric cancers combined has declined by more than 50%.
Teresa A. McNulty is Channel Content Director of Contemporary Pediatrics.






